Susceptibilidade das células beta-pancreáticas ao SARS-CoV-2: uma revisão integrativa
DOI:
https://doi.org/10.53843/bms.v8i12.610Palabras clave:
COVID-19, Sars-CoV-2, Diabetes Mellitus, Células Secretoras de Insulina, EndocrinologiaResumen
Introdução: A pandemia causada pela SARS-CoV-2 trouxe inúmeros desafios à sociedade, gerando uma enorme carga global de saúde em busca de sua compreensão. Sabe-se que a SARS-CoV-2 possui manifestações que vão além do acometimento respiratório. Ao longo do tempo, o conhecimento acerca dos mecanismos e tropismos do vírus se modificou, permitindo uma maior compreensão da fisiopatologia da COVID-19. Acerca do potencial acometimento endócrino causado pelo SARS-CoV-2, é possível observar que as células beta-pancreáticas são suscetíveis à infecção pelo vírus, sendo válida a investigação acerca de tal correlação. Por tal motivo, procuramos estabelecer essa relação entre a infecção pelo SARS-CoV-2 e seus efeitos sobre as células beta pancreáticas.
Metodologia: As buscas foram realizadas com palavras-chave definidas, encontrando estudos indexados no banco de dados eletrônicos PubMed.
Resultado: Após a leitura completa dos 63 artigos selecionados por meio dos critérios de inclusão e exclusão, foi possível observar que 42 retratam algum grau de susceptibilidade das células beta-pancreáticas à infecção por SARS-Cov-2. O presente trabalho procurou demonstrar que a infecção pelo SARS-CoV-2 está intimamente relacionada com efeitos deletérios às células beta pancreáticas.
Conclusão: Através da revisão dos artigos selecionados, chegamos à conclusão de que o SARS-CoV-2 é um vírus que acomete o corpo humano de diversas maneiras diferentes, podendo gerar Diabetes Mellitus (DM) caso afete o funcionamento das células β. Ressaltamos a importância de mais estudos na área, visto que as consequências da pandemia do COVID-19 acompanharão a humanidade por um longo tempo, sendo de extrema relevância para a prática médica dos próximos anos.
Métricas
Citas
MONTEFUSCO, L. et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nature Metabolism, v. 3, 774-785, 2021. DOI: 10.1038/s42255-021-00407-6
ABRAMCZYK, U. et al. Consequences of COVID-19 for the Pancreas. International Journal of Molecular Sciences, v. 23, 2022. DOI: 10.3390/ijms23020864
MÜLLER, J.A., Groß, R., Conzelmann, C. et al. SARS-CoV-2 infects and replicates in cells of the human endo-crine and exocrine pancreas. Nature Metabolism, v. 3, 149–165 2021. DOI: 10.1038/s42255-021-00347-1
WU, CT. et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metabolism, v. 33, 2021. DOI: 10.1016/j.cmet.2021.05.013
STEENBLOCK, C. et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nature communications, v. 12, 2021. DOI: 10.1038/s41467-021-23886-3
HOSSEINI, S. H.; ROUSHENAS, S.; BAZHDAN, L.; A challeging case of COVID-19: a COVID-19 positive ado-lescent presented with severe diabetic ketoacidosis, re-sistant hypertension. BMC Endocrine Disorders, v. 22, 2022. DOI: https://doi.org/10.1186/s12902-022-00979-8
MEMOM, B.; ABDELALIM, E. M. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell stem cell, v. 27, 2020. DOI: 10.1016/j.stem.2020.06.015
HAYDEN, M. R. An immediate and long-term complication of COVID-19 may be type 2 diabetes mellitus: the central role of beta-cell dysfunction, apoptosis and exploration of possible mechanisms. Cells, v. 9, 2020. DOI: 10.3390/cells9112475
MUNIANGI-MUHITU, HERMINE et al. Covid-19 and dia-betes: a complex bidirectional relationship. Frontiers in en-docrinology, v. 11, 2020. DOI: https://doi.org/10.3389/fendo.2020.582936
XIE, LINGLI et al. COVID-19 and diabetes: a comprehen-sive review of angiotensin converting enzyme 2, mutual ef-fects and pharmacotherapy. Frontiers in endocrinology, v.12, 2021.DOI: https://doi.org/10.3389/fendo.2021.772865
AL-KURAISHY, HAYDER M. et al. COVID-19 in relation to hyperglycemia and diabetes mellitus. Frontiers in cardio-vascular medicine, v.8, 2021. DOI: https://doi.org/10.3389/fcvm.2021.644095
EL-HUNEIDI, W. et al. Expression of SARS-CoV-2 recep-tor “ACE2” in human pancreatic beta cells: to be or not to be! Islets, v.13, 2021. DOI: 10.1080/19382014.2021.1909970
EL-HUNEIDI, W. et al. Expression profile of SARS-CoV-2 host receptors in humans pancreatic islets revealed up-regulation of ACE2 in diabetic donors. Biology, v. 9, 2020. doi: 10.3390/biology9080215
RANGU, R. et al. Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2. Journal of Molecular Endocrinology, v. 69, 2022. DOI: https://doi.org/10.1530/JME-21-0282
SABR, SOPHIA et al. Interactions between diabetes and COVID-19: A narrative review. World journal of diabetes, v. 12, 2021. DOI: 10.4239/wjd.v12.i10.1674
VAN DER HEIDE, VERENA et al. Limited extente and consequences of pancreatic SARS-CoV-2 infection. Cell Reports, v. 38, 2022. DOI: 10.1016/j.celrep.2022.110508
IBRAHIM, S.; MONACO, G. S. F.; SIMS, E. K. Not so sweer and simple: impacts of SARS-CoV-2 on the beta cell. Islets, v.13, 2021. DOI: 10.1080/19382014.2021.1909970
GERAVANDI, SHIRIN et al. SARS-CoV-2 and pancreas: a potential pathological interaction? Trends in endocrinology and metabolism: TEM, v.32, 2021. DOI: 10.1016/j.tem.2021.07.004
COATE, KATIE C. et al. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvascula-ture and ducts of human pancreas but are not enriched in beta cells. Cell metabolism, v.32, 2020. DOI: 10.1016/j.cmet.2020.11.006
SZLACHCIC, WOJCIECH J. et al. SARS-CoV-2 infects an in vitro model of the human developing pancreas through endocytosis. iScience, v. 25, 2022. DOI: 10.1016/j.isci.2022.104594
FIGNANI, DANIELA et al. SARS-CoV-2 receptor angio-tensin-I-converting eczema type 2 (ACE2) is expressed in human pancreatic beta-cells and in the human pancreas microvasculature. Frontiers in endocrinology, v. 11, 2020. https://doi.org/10.3389/fendo.2020.596898
HOLLSTEIN, TIM et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nature metabolism, v. 2, 2020.https://doi.org/10.1038/s42255-020-00281-8
ACCIOLY, DOMENICO. Can COVID-19 cause diabetes? Nature metabolism, vol.3, 2021. doi: 10.1038/s42255-020-00339-7
GAVKARE, A. M. et al. COVID-19 associated diabetes mellitus: a review. World journal of diabetes, v. 13, 2022.doi: 10.4239/wjd.v13.i9.729
JEDRZEJAK, ANNA P. et al. Diabetes and SARS-CoV-2-Is there a mutual connection? Frontiers in cell and devel-opmental biology, v. 10, 2022. https://doi.org/10.3389/fcell.2022.913305
ZORENA, K. et al. Environmental factors and the risk of developing type 1 diabetes-old disease and new data. Biol-ogy, v. 11, 2022. doi: 10.3390/biology11040608
SHAO, SIYING et al. Interaction of severe acute respirato-ry syndrome coronavirus 2 and diabetes. Frontiers in en-docrinology, v. 12, 2021. https://doi.org/10.3389/fendo.2021.731974
SIDDIQUI, R. S.; ZIRKIYRVA, M.; SALIAK, M. Onset of ketosis-prone diabetes in the setting of COVID-19 infection. Cureus, v. 12, 2020. doi: 10.7759/cureus.10779
PAE, EUNG-KWON; HARPER, R. M. Potential mecha-nisms underlying hypoxia-induced diabetes in a rodent model: implications for COVID-19. Children (Basel, Swit-zerland), v. 8, 2021.https://doi.org/10.3390/children8121178
MINE, KEIICHIRO et al. SARS-CoV-2 infection and pan-creatic beta cell failure. Biology, v. 11, 2021.doi: 10.3390/biology11010022
CLARK, A. L.; MIRMIRA, R. G. SARS-CoV-2 infection os islets beta cells: evidence and implications. Cell reports. Medicine, v.2, 2021. https://doi.org/10.1016/j.xcrm.2021.100380
SINGH, A. K.; KHUNTI, K. COVID-19 and diabetes, Annu-al review of medicine. v. 73, 2022. https://doi.org/10.1146/annurev-med-042220-011857
KANETO, HIDEAKI et al. Molecular mechanism of pan-creatic beta-cell failure in type 2 diabetes mellitus. Biomed-icines, v. 10, 2022.doi: 10.3390/biomedicines10040818
PELLE, MARIA CHIARA et al. COVID-19 and diabetes-two giants colliding: from pathophysiology to management. Frontiers in endocrinology, v. 13, 2022. https://doi.org/10.3389/fendo.2022.974540
VLAD, ADRIAN et al. Increased incidence of type 1 diabe-tes during the COVID-19 pandemic in Romanian Children. Medicina (Kaunas, Lithuania), v. 57, 2021. DOI: 10.3390/medicina57090973
GARDNER, G.; FRAKER, C. A. Natural killer cells as key mediators in type 1 diabetes immunopathology. Frontiers in immunology, v. 12, 2021. https://doi.org/10.3389/fimmu.2021.722979
MICHALAKIS, K.; ILIAS, I. COVID-19 and hyperglyce-mia/diabetes. World journal of diabetes, v. 12, 2021. doi: 10.4239/wjd.v12.i5.642 See More
YANG, LIULIU et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus in-fection in human cells and organoids. Cell stem cell, v. 27, 2020. DOI: 10.1016/j.stem.2020.06.015
DALY, JL; et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020; vol. 370(6518):861-865. doi: 10.1126/science.abd3072.
CANTUTI-CASTELVETRI, L; et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020; vol. 370(6518):856-860. doi: 10.1126/science.abd2985.
LI ZL; BUCK M. Neuropilin-1 assists SARS-CoV-2 infec-tion by stimulating the separation of Spike protein S1 and S2. Biophys J. 2021; vol. 120(14):2828-2837. doi: 10.1016/j.bpj.2021.05.026]
YAMAMOTO, K; TAKESHITA, H; RAKUGI, H. ACE2, Angiotensin 1-7 and skeletal muscle: review in the era od COVID-19. Clinical Science (2020), vol. 134. Page: 3047–3062. Doi.org/10.1042/CS20200486
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Anna Cláudia Nunes, Anna Lucinda Truyts Lima Vaz Guimarães, Ciro Ferrari de Souza, Igor de Oliveira Freire Monteiro, Jean Carlos Pacheco Nepe, Júlia de Oliveira Machado, Lucas Felippe do Carmo Miranda, Pedro Henrique Rosa Nogueira, Renan Felipe Franco Moura, Vinícius Costa da Silva, Renato Rizo Ventura
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Las licencias de usuario definen cómo los lectores y el público en general pueden utilizar el artículo sin requerir otros permisos. Las licencias públicas Creative Commons proporcionan un conjunto estándar de términos y condiciones que los creadores y otros titulares de derechos pueden utilizar para compartir obras originales de autoría y otros materiales sujetos a derechos de autor y otros derechos específicos especificados en la licencia pública disponible en https:// creativecommons.org /licenses/by/4.0/deed.pt_BR. Al utilizar la Licencia Pública Internacional 4.0, los Estudiantes de Medicina de Brasil (BMS) otorgan al público permiso para utilizar el material publicado en los términos y condiciones especificados y acordados por la revista. Al ejercer los derechos de licencia, los autores aceptan y aceptan estar sujetos a los términos y condiciones de la Licencia Pública Internacional Creative Commons Attribution 4.0.
